Journal Article

Novel recombinant human thyroid-stimulating hormone in aiding postoperative assessment of patients with differentiated thyroid cancer—phase I/II study

Zhang, Xin, Li, Xiao-Yi, He, Bao-Xia, Xu, Jin-Guo, Yang, Ai-Min, Jia, Jian-Min, Sun, Di, Zhang, Shao-Qiang, Chen, Fang-Ni, Yang, Hui, Zhang, Ying-Qiang, Geng, Qian-Qian, Lin, Yan-Song, Wu, Li-Qing, Zhang, Ya-Jing, Mu, Zhuan-Zhuan, Ding, Yong, Chen, Kai, Niu, Na, Gao, Zai-Rong

2022

Overview

Abstract PurposeThyroid hormone withdrawal (THW) inevitably induced hypothyroidism in patients with differentiated thyroid cancer (DTC), and we aimed to evaluate the safety and efficacy of a novel recombinant human thyroid-stimulating hormone (rhTSH, ZGrhTSH) as an alternative of THW in China.MethodsTotally, 64 DTC patients were enrolled with 24 in the dose-escalation cohort equally grouped into 0.9 mg × 1 day, 0.9 mg × 2 day, 1.8 mg × 1 day, and 1.8 mg × 2 day dosage, and 40 further enrolled into 0.9 mg × 2 day dose-expansion cohort. All patients underwent both ZGrhTSH phase and levothyroxine (L-T4) withdrawal phase for self-comparison in terms of TSH levels, the radioactive iodine (RAI) uptake, stimulated thyroglobulin level, and the quality of life (QoL).ResultsIn ZGrhTSH phase, no major serious adverse events were observed, and mild symptoms of headache were observed in 6.3%, lethargy in 4.7%, and asthenia in 3.1% of the patients, and mostly resolved spontaneously within 2 days. Concordant RAI uptake was noticed in 89.1% (57/64) of the patients between ZGrhTSH and L-T4 withdrawal phases. The concordant thyroglobulin level with a cut-off of 1 μg/L was noticed in 84.7% (50/59) of the patients without the interference of anti-thyroglobulin antibody. The QoL was far better during ZGrhTSH phase than L-T4 withdrawal phase, with lower Billewicz (− 51.30 ± 4.70 vs. − 39.10 ± 16.61, P < 0.001) and POMS (91.70 ± 16.70 vs. 100.40 ± 22.11, P = 0.011) scores which indicate the lower the better. Serum TSH level rose from basal 0.11 ± 0.12 mU/L to a peak of 122.11 ± 42.44 mU/L 24 h after the last dose of ZGrhTSH. In L-T4 withdrawal phase, a median of 23 days after L-T4 withdrawal was needed, with the mean TSH level of 82.20 ± 31.37 mU/L. The half-life for ZGrhTSH clearance was about 20 h.ConclusionThe ZGrhTSH held the promise to be a safe and effective modality in facilitating RAI uptake and serum thyroglobulin stimulation, with better QoL of patients with DTC compared with L-T4 withdrawal.

• Publisher: Springer Nature B.V
• Subject: Antibodies / Asthenia / Cancer / Half-life / Hypothyroidism / Iodine / Lethargy / Quality of life / Thyroglobulin / Thyroid cancer / Thyroid gland / Thyroid-stimulating hormone / Thyroxine